Resumen
The treatment options for advanced well differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are scant, especially after the failure of first-line, anthracycline-based treatment, when trabectedin is one of the most active agents currently approved. Thus, the identification of biological characteristics allowing an efficient patients stratification in this setting appears mandatory. Here, applying a grading-based stratification, we showed that trabectedin may be more active against low-grade LPS (i.e., WDLPS and low-grade DDLPS) than in high-grade LPS (i.e., high-grade DDLPS). If confirmed, our data might allow the implementation of grading as a tool patients? stratification in this setting.